Implantation of a capsular tension ring effectively reduces the percentage area of posterior capsular opacification (PCO) and the Nd:YAG laser capsulotomy rate in patients with highly myopic eyes, according to researchers in Albania and Turkey.
Implantation of a capsular tension ring effectively reduces the percentage area of posterior capsular opacification (PCO) and the Nd:YAG laser capsulotomy rate in patients with highly myopic eyes, according to researchers in Albania and Turkey.
The researchers conducted a prospective, single-surgeon, standardized-surgical-procedure fellow-eye comparison trial in which 34 highly myopic patients had phacoemulsification surgery.
All of the patients received an acrylic intraocular lens (IOL) and a capsular tension ring in one eye; the other eye served as a control by receiving the IOL only. The researchers documented PCO within the capsulorhexis overlap using standardized digital retroillumination images at least 2 years postoperatively and scored the percentage area of PCO. The researchers also determined the PCO score and the incidence of Nd: YAG capsulotomy of the eyes.
The researchers found that the PCO score of the eyes with a capsular tension ring was significantly lower (5.9 ± 4.3) than that of the controls (22.3 ± 12.2) (P P = 0.025).
"Even though [capsular tension ring] implantation is not routine in cataract surgery, its implantation should be considered in high myopic patients who have zonular instability and retinal pathologies posing risk for Nd:YAG capsulotomy," the researchers wrote.
Read the entire study in the Indian Journal of Ophthalmology.
AAO 2024: Transient vision loss with Alexander Fein, MD
October 21st 2024Alexander Fein, MD, spoke with the Eye Care Network to share how to approach a patient presenting with transient vision loss, what this type of vision loss can mean, and what additional testing might be needed to determine the best plan for care.
AAO 2024: Optimal pupil size reduction percentage for near vision improvement in presbyopia
October 21st 2024Jennifer Loh, MD, shared insights from on her presentation at the American Academy of Ophthalmology meeting in Chicago on the effects of CSF-1, which is the lowest effective concentration of pilocarpine approved in the United States.